Officials: rising GLP‑1 drug costs outpace value; school administrators to notify affected employees of options

Summary

At a Manchester School Committee meeting, a consultant and district leaders described steep cost increases for GLP‑1 weight‑loss drugs, outlined how that could affect benefits and premiums, and agreed to notify roughly 168–169 employees about alternatives including use of health‑savings accounts and direct‑to‑consumer pricing.

At a public meeting of the Manchester Board of School Committee, a consultant warned that coverage of GLP‑1 medications for weight loss has driven steep health‑plan costs, and committee members pressed the administration to notify affected employees of alternative purchase and payment options.

Tom DeLacy, principal consultant for Workplace Benefit Solutions Hub, told the committee that GLP‑1 drugs—originally developed for diabetes but now prescribed for weight loss—have sharply increased the district’s medical claims costs. “The cost for the Manchester School District increased tenfold from fiscal 23 to fiscal 25 and nearly fivefold in the last year alone,” DeLacy said. He said several large carriers and public plans have recently dropped or limited coverage because of the “prohibitive expense.”

The discussion matters because the district’s self‑insured plan would shoulder most of any continued coverage. DeLacy said his projection for this fiscal period was roughly $2.5 million in total cost, “$2,000,000 borne…

Officials: rising GLP‑1 drug costs outpace value; school administrators to notify affected employees of options

Summary

Subscribe to keep reading